在常规实践中识别患者以开具降压药处方的策略:证据综述

IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE
James P. Sheppard, Athanase Benetos, Jonathan Bogaerts, Danijela Gnjidic, Richard J. McManus
{"title":"在常规实践中识别患者以开具降压药处方的策略:证据综述","authors":"James P. Sheppard, Athanase Benetos, Jonathan Bogaerts, Danijela Gnjidic, Richard J. McManus","doi":"10.1007/s11906-024-01293-5","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>To summarise the evidence regarding which patients might benefit from deprescribing antihypertensive medications.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Older patients with frailty, multi-morbidity and subsequent polypharmacy are at higher risk of adverse events from antihypertensive treatment, and therefore may benefit from antihypertensive deprescribing. It is possible to examine an individual’s risk of these adverse events, and use this to identify those people where the benefits of treatment may be outweighed by the harms. While such patients might be considered for deprescribing, the long-term effects of this treatment strategy remain unclear.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Evidence now exists to support identification of those who are at risk of adverse events from antihypertensive treatment. These patients could be targeted for deprescribing interventions, although the long-term benefits and harms of this approach are unclear.</p><h3 data-test=\"abstract-sub-heading\">Perspectives</h3><p>Randomised controlled trials are still needed to examine the long-term effects of deprescribing in high-risk patients with frailty and multi-morbidity.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"38 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Strategies for Identifying Patients for Deprescribing of Blood Pressure Medications in Routine Practice: An Evidence Review\",\"authors\":\"James P. Sheppard, Athanase Benetos, Jonathan Bogaerts, Danijela Gnjidic, Richard J. McManus\",\"doi\":\"10.1007/s11906-024-01293-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose of Review</h3><p>To summarise the evidence regarding which patients might benefit from deprescribing antihypertensive medications.</p><h3 data-test=\\\"abstract-sub-heading\\\">Recent Findings</h3><p>Older patients with frailty, multi-morbidity and subsequent polypharmacy are at higher risk of adverse events from antihypertensive treatment, and therefore may benefit from antihypertensive deprescribing. It is possible to examine an individual’s risk of these adverse events, and use this to identify those people where the benefits of treatment may be outweighed by the harms. While such patients might be considered for deprescribing, the long-term effects of this treatment strategy remain unclear.</p><h3 data-test=\\\"abstract-sub-heading\\\">Summary</h3><p>Evidence now exists to support identification of those who are at risk of adverse events from antihypertensive treatment. These patients could be targeted for deprescribing interventions, although the long-term benefits and harms of this approach are unclear.</p><h3 data-test=\\\"abstract-sub-heading\\\">Perspectives</h3><p>Randomised controlled trials are still needed to examine the long-term effects of deprescribing in high-risk patients with frailty and multi-morbidity.</p>\",\"PeriodicalId\":10963,\"journal\":{\"name\":\"Current Hypertension Reports\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-02-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Hypertension Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11906-024-01293-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-024-01293-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

最新研究结果年老体弱、身患多种疾病并继发多种药物治疗的患者从降压治疗中发生不良事件的风险较高,因此可能会从降压治疗中获益。可以对个人发生这些不良事件的风险进行检查,并据此确定哪些人的治疗利大于弊。虽然可以考虑对这类患者取消处方,但这种治疗策略的长期效果仍不明确。摘要目前已有证据支持识别那些有可能因降压治疗而发生不良事件的患者。尽管这种方法的长期益处和危害尚不明确,但可以针对这些患者采取减药干预措施。展望仍需进行随机对照试验,以研究对体弱多病的高危患者减药的长期效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Strategies for Identifying Patients for Deprescribing of Blood Pressure Medications in Routine Practice: An Evidence Review

Strategies for Identifying Patients for Deprescribing of Blood Pressure Medications in Routine Practice: An Evidence Review

Purpose of Review

To summarise the evidence regarding which patients might benefit from deprescribing antihypertensive medications.

Recent Findings

Older patients with frailty, multi-morbidity and subsequent polypharmacy are at higher risk of adverse events from antihypertensive treatment, and therefore may benefit from antihypertensive deprescribing. It is possible to examine an individual’s risk of these adverse events, and use this to identify those people where the benefits of treatment may be outweighed by the harms. While such patients might be considered for deprescribing, the long-term effects of this treatment strategy remain unclear.

Summary

Evidence now exists to support identification of those who are at risk of adverse events from antihypertensive treatment. These patients could be targeted for deprescribing interventions, although the long-term benefits and harms of this approach are unclear.

Perspectives

Randomised controlled trials are still needed to examine the long-term effects of deprescribing in high-risk patients with frailty and multi-morbidity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Hypertension Reports
Current Hypertension Reports 医学-外周血管病
CiteScore
10.50
自引率
0.00%
发文量
65
审稿时长
6-12 weeks
期刊介绍: This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信